$29.10
$0.00 (0.00%)
End-of-day quote: 05/17/2024
NasdaqGM:SUPN
Supernus Pharmaceuticals Annual Report
| Year | Year | 2023 | 2022 | 2021 | 2011 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$607.52M | $667.24M | $579.78M | $0.80M | $520.40M | $392.76M | $408.90M | $302.24M | $215.00M | $147.47M | $92.68M | $12.02M | $1.48M | |
| GM % | Gross Margin % |
|
86.21% | 86.93% | 87.05% | 100.00% | 89.92% | 95.76% | 96.24% | 94.97% | 94.43% | 94.29% | 93.79% | 90.81% | 100.00% | |
| OM | Operating Margin |
|
2.21% | 6.84% | 13.71% | 0.00% | 35.36% | 37.83% | 35.33% | 32.93% | 25.22% | 14.13% | -5.69% | 0.00% | 0.00% | |
| EPS | Earnings Per Share |
|
$0.00 | $1.14 | $2.65 | $0.98 | $2.36 | $2.10 | $2.05 | $1.08 | $1.78 | $0.32 | $-0.24 | $-2.18 | $-2.72 | $-16.60 |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| PR % | Payout Ratio % |
|
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.00% | -0.00% | -0.00% | |
| Sha. | Shares |
|
54.72m | 54.25m | 53.26m | 1.66m | 52.87m | 52.53m | 52.32m | 51.31m | 49.97m | 49m | 42.97m | 39.98m | 30.62m | |
| OCF | Operating Cash Flow |
|
$111.09M | $116.83M | $127.13M | $-36.19M | $138.40M | $143.13M | $128.99M | $114.64M | $66.81M | $34.52M | $-24.50M | $-57.95M | $-47.20M | |
| FCF | Free Cash Flow |
|
$118.70M | $116.41M | $125.08M | $-36.88M | $134.95M | $140.39M | $128.14M | $112.61M | $65.21M | $30.02M | $14.70M | $-59.60M | $-47.95M | |
| FCFS | Free Cash Flow Per Share |
|
$2.03 | $2.17 | $2.36 | $-22.97 | $2.56 | $2.70 | $2.46 | $2.22 | $1.32 | $0.68 | $-0.59 | $-1.87 | $-2.75 |
